Gordie Nye News

Atlantic Therapeutics appoints Gordie Nye as Chairman

Seroba’s investee company, Atlantic Therapeutics, which is focused on treating conditions of the pelvic floor and surrounding tissues, has appointed Gordie Nye as its Chairman.

After working with Gillette and Reebok, Gordie Nye forged his career as a CEO and Director of venture and private equity-backed medical device start-ups and buyouts. Of particular note are A-Company Orthodontics, Critikon and ZELTIQ Aesthetics, all of which saw excellent returns for investors. Nye is currently CEO of R2 Dermatology, a start-up that is set to commercialise a Harvard University technology – familiar territory for Nye who did the same at ZELTIQ, the maker of CoolSculpting, arguably the most valuable device company in the Aesthetics industry.

Atlantic Therapeutics CEO, Steve Atkinson, previously teamed up with Nye at ZELTIQ and Critikon. Atkinson says: “I am delighted Gordie has joined Atlantic Therapeutics as Chairman.  His involvement is an endorsement of the huge potential for INNOVO® and Gordie’s expertise in marketing medical devices to consumers will be invaluable to management as we strive to build value for our company and investors.”

Nye says “Typically resulting in incontinence and/or poor sexual health, a weak pelvic floor adversely affects the dignity, social life, and relationships of millions of people. Few conditions are so widespread yet so poorly served by the healthcare industry.  Surgery is a last resort, and conservative treatments in this category typically involve internally inserted devices that can be embarrassing and are unpleasant to use.  INNOVO® is safe, effective, wearable, and is an embarrassment-free device to restore pelvic floor strength.  As Chairman of Atlantic Therapeutics, I look forward to working with Steve and his team to achieve widespread adoption of INNOVO®.”

Ends.

For further information: Please contact Vicky La Touche-Price, Seroba Life Sciences on +353 1 6334028 or visit RestoreTheFloor.

Recent Articles

Cancer Killers

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board

Hamilton, ON & Boston, MA – January 13, 2020 – Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology […]

Read More
Quanta News

Quanta Announces Collaboration with B. Braun Avitum UK Ltd

Alcester, Warwickshire, UK, 13 January 2020: Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology […]

Read More
Pq Bypass News 2

CMS Approves Coverage for PQ Bypass TORUS 2 IDE Trial

Seroba’s portfolio company, PQ Bypass Inc, a medical device company bringing new advancements to the treatment of peripheral artery disease […]

Read More
Cordella PA Sensor Coin

Endotronix Announces Positive Data from the SIRONA First-in-Human Trial for the Cordella™ PA Pressure Sensor System

LISLE, IL – November 18, 2019 – Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top